medicinal-chemistry-2018-scientifictracks

7 / 15

Page 49
Notes:
conferenceseries.com
Volume 8 Medicinal Chemistry
ISSN: 2161-0444 Medicinal Chemistry 2018
June 14-15, 2018
June 14-15, 2018 | Barcelona, Spain
10th World Congress on
Medicinal Chemistry and Drug Design
Recombinant ricin nanoparticles design for CXCR4+ cancer cell therapy
Raquel Díaz, Victor Pallarès, Olivia Cano-Garrido, Naroa Serna, Laura Sánchez-Garcia, Aïda Falgàs, Mireia Pesarrodona, Ugutz Unzueta, Alejandro
Sánchez-Chardi, Julieta M. Sánchez, Isolda Casanova, Esther Vázquez, Ramón Mangues and Antonio Villaverde
Universitat Autònoma de Barcelona, Spain
Biomedical Research Institute Sant Pau (IIB-Sant Pau) and Josep Carreras Research Institute Hospital de la Santa Creu i Sant Pau, Spain
The potent ligand T22, that specifically binds the CXCR4+ receptor, overexpressed in some cancer cells, was engineered
to be attached to the N-terminus of the mutated A chain of the plant toxin ricin fused to a 6xHis tag in the C-terminus.
The soluble recombinant protein T22mRTAH6 spontaneously self-assembled as protein-only regular nanoparticles of about
12nm in size, capable of CXCR4 dependent cellular internalization and effective cytotoxic effect in vitro. Meanwhile, the
insoluble version of the protein presented moderate free-protein release inducing to a partial cytotoxic effect in the cells. The
T22mRTAH6 nanostructured construct was also tried in mouse models of acute myeloid leukemia, where it proved to reduce
dramatically the disease affectation of clinically relevant organs. The functionalized protein nanoparticles are then proposed as
suitable prototypes for antitumor carcinogenic therapies based on self-mediated intracellular drug delivery.
Biography
Raquel Díaz is studying her PhD program at Univerity Autonomous of Barcelona .
Raquel Díaz et al., Med chem (Los Angeles) 2018, Volume 8
DOI: 10.4172/2161-0444-C1-039